BRPI0921802A2 - combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor - Google Patents

combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor

Info

Publication number: BRPI0921802A2
Authority: BR; Brazil
Prior art keywords: inhibitor; pi3k; phosphatidylinositol; kinase; combination
Prior art date: 2008-10-31

Application number

BRPI0921802A

Other languages

English (en)

Inventor

Carlos Garcia-Echeverria

Sauveur-Michel Maira

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-31

Filing date

2009-10-29

Publication date

2016-09-27

2009-10-29 Application filed by Novartis Ag filed Critical Novartis Ag

2016-09-27 Publication of BRPI0921802A2 publication Critical patent/BRPI0921802A2/pt

2018-03-13 Publication of BRPI0921802A8 publication Critical patent/BRPI0921802A8/pt

Links

229940124302 mTOR inhibitor Drugs 0.000 title 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0921802A 2008-10-31 2009-10-29 uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. BRPI0921802A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08168044		2008-10-31
PCT/EP2009/064274 WO2010049481A1 (en)	2008-10-31	2009-10-29	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Publications (2)

Publication Number	Publication Date
BRPI0921802A2 true BRPI0921802A2 (pt)	2016-09-27
BRPI0921802A8 BRPI0921802A8 (pt)	2018-03-13

Family

ID=40332588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921802A BRPI0921802A8 (pt)	2008-10-31	2009-10-29	uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.

Country Status (12)

Country	Link
US (3)	US20110195966A1 (pt)
EP (1)	EP2349275B1 (pt)
JP (4)	JP2012506898A (pt)
KR (1)	KR20110090911A (pt)
CN (2)	CN102202668A (pt)
AU (1)	AU2009309616B2 (pt)
BR (1)	BRPI0921802A8 (pt)
CA (1)	CA2736361C (pt)
ES (1)	ES2627677T3 (pt)
MX (1)	MX2011004585A (pt)
RU (2)	RU2538683C2 (pt)
WO (1)	WO2010049481A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100047338A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
AU2010210422A1 (en)	2009-02-05	2011-08-18	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
GB2478556A (en) *	2010-03-09	2011-09-14	Myrovlytis Technology Ventures Ltd	A composition for use in the treatment of Birt-Hogg-Dubô sydrome
WO2012110953A1 (en) *	2011-02-16	2012-08-23	Novartis Ag	Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
JP6130305B2 (ja)	2011-02-23	2017-05-17	インテリカイン，エルエルシー	キナーゼ阻害剤の組み合わせおよびそれらの使用
EP2683444A1 (en) *	2011-03-07	2014-01-15	Fondazione Telethon	Tfeb phosphorylation inhibitors and uses thereof
JP6086902B2 (ja) *	2011-04-25	2017-03-01	ノバルティスアーゲー	ホスファチジルイノシトール−３−キナーゼ（ＰＩ３Ｋ）阻害剤およびｍＴＯＲ阻害剤の組み合わせ
WO2012151562A1 (en)	2011-05-04	2012-11-08	Intellikine, Llc	Combination pharmaceutical compositions and uses thereof
EP2771337B1 (en)	2011-09-27	2017-08-02	Novartis AG	3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh
JP6114296B2 (ja) *	2011-11-08	2017-04-12	インテリカイン，エルエルシー	複数の医薬品を使用した治療レジメン
WO2013078440A2 (en) *	2011-11-23	2013-05-30	Intellikine, Llc	Enhanced treatment regimens using mtor inhibitors
UY34632A (es) *	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2012112128A (ru) *	2012-03-29	2013-10-10	Холин Максим Николаевич	ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2968281B1 (en)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
KR20150127720A (ko)	2013-03-14	2015-11-17	유니버시티 오브 매릴랜드, 발티모어	안드로겐 수용체 하향 조절제 및 그의 용도
WO2014141104A1 (en)	2013-03-14	2014-09-18	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN105339001A (zh)	2013-03-15	2016-02-17	基因泰克公司	治疗癌症和预防癌症耐药性的方法
MY182082A (en) *	2013-05-01	2021-01-18	Hoffmann La Roche	Biheteroaryl compounds and uses thereof
WO2015023710A1 (en)	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN103483345B (zh) *	2013-09-25	2016-07-06	中山大学	Pi3k激酶抑制剂、包含其的药物组合物及其应用
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
EP3283127B1 (en) *	2015-04-15	2020-02-26	University of Massachusetts	Compositions and methods for xi chromosome reactivation
WO2016185443A1 (en)	2015-05-20	2016-11-24	Novartis Ag	Pharmaceutical combination of everolimus with dactolisib
WO2018096402A1 (en)	2016-11-23	2018-05-31	Novartis Ag	Methods of enhancing immune response with everolimus, dactolisib or both
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
KR20210158019A (ko)	2020-06-23	2021-12-30	주식회사 온코빅스	포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
CN112294967A (zh) *	2020-09-30	2021-02-02	四川大学	一种mTOR抑制剂与抗癌药物的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20021015A2 (en) *	2000-06-26	2004-02-29	Stressgen Biotechnologies Corp	Human papilloma virus treatment
TW200626610A (en) *	2004-10-13	2006-08-01	Wyeth Corp	Analogs of 17-hydroxywortmannin as PI3K inhibitors
BRPI0613692A2 (pt) *	2005-07-20	2011-01-25	Novartis Ag	combinação farmacêutica e uso da mesma
EP1954699B1 (en) *	2005-11-22	2012-09-19	Kudos Pharmaceuticals Ltd	PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
TW200738725A (en) *	2006-01-25	2007-10-16	Osi Pharm Inc	Unsaturated mTOR inhibitors
WO2007120897A2 (en) *	2006-04-13	2007-10-25	The Trustees Of Columbia University In The City Of New York	Compositions and intraluminal devices for inhibiting vascular stenosis
ES2381895T3 (es) *	2007-02-06	2012-06-01	Novartis Ag	Inhibidores de PI 3-quinasa y métodos para su uso
US9370508B2 (en) *	2007-02-20	2016-06-21	Novartis Ag	Imidazoquinolines as dual lipid kinase and mTOR inhibitors
EP2231147A2 (en) *	2007-12-13	2010-09-29	Novartis AG	Combinations of therapeutic agents for treating cancer

2009
- 2009-10-29 BR BRPI0921802A patent/BRPI0921802A8/pt not_active IP Right Cessation
- 2009-10-29 EP EP09744391.5A patent/EP2349275B1/en not_active Not-in-force
- 2009-10-29 WO PCT/EP2009/064274 patent/WO2010049481A1/en not_active Ceased
- 2009-10-29 ES ES09744391.5T patent/ES2627677T3/es active Active
- 2009-10-29 JP JP2011533721A patent/JP2012506898A/ja not_active Withdrawn
- 2009-10-29 MX MX2011004585A patent/MX2011004585A/es active IP Right Grant
- 2009-10-29 AU AU2009309616A patent/AU2009309616B2/en not_active Ceased
- 2009-10-29 KR KR1020117009771A patent/KR20110090911A/ko not_active Ceased
- 2009-10-29 CN CN2009801431736A patent/CN102202668A/zh active Pending
- 2009-10-29 US US13/123,956 patent/US20110195966A1/en not_active Abandoned
- 2009-10-29 CN CN201510402018.9A patent/CN105030784A/zh active Pending
- 2009-10-29 RU RU2011121508/15A patent/RU2538683C2/ru not_active IP Right Cessation
- 2009-10-29 CA CA2736361A patent/CA2736361C/en not_active Expired - Fee Related
2014
- 2014-04-15 RU RU2014115188/15A patent/RU2014115188A/ru not_active Application Discontinuation
- 2014-09-05 JP JP2014181069A patent/JP2015013883A/ja not_active Withdrawn
2015
- 2015-11-24 US US14/950,869 patent/US20160136175A1/en not_active Abandoned
2016
- 2016-07-06 JP JP2016134514A patent/JP2017002058A/ja not_active Ceased
2018
- 2018-01-16 US US15/872,043 patent/US20180133226A1/en not_active Abandoned
- 2018-07-20 JP JP2018136756A patent/JP2018197243A/ja active Pending

Also Published As

Publication number	Publication date
US20160136175A1 (en)	2016-05-19
MX2011004585A (es)	2011-06-01
ES2627677T3 (es)	2017-07-31
JP2015013883A (ja)	2015-01-22
EP2349275B1 (en)	2017-03-08
CA2736361C (en)	2017-10-10
CN105030784A (zh)	2015-11-11
RU2014115188A (ru)	2015-10-20
AU2009309616A1 (en)	2010-05-06
KR20110090911A (ko)	2011-08-10
AU2009309616A2 (en)	2011-07-07
BRPI0921802A8 (pt)	2018-03-13
JP2012506898A (ja)	2012-03-22
US20110195966A1 (en)	2011-08-11
US20180133226A1 (en)	2018-05-17
EP2349275A1 (en)	2011-08-03
RU2011121508A (ru)	2012-12-10
JP2018197243A (ja)	2018-12-13
CN102202668A (zh)	2011-09-28
AU2009309616B2 (en)	2014-02-13
WO2010049481A1 (en)	2010-05-06
CA2736361A1 (en)	2010-05-06
JP2017002058A (ja)	2017-01-05
RU2538683C2 (ru)	2015-01-10

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-11-10	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2021-03-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2601 DE 10-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0921802A2 (pt)	2016-09-27	combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
IL280173A (en)	2021-03-01	Inhibitors of brutons tyrosine kinase
BRPI0921156A2 (pt)	2016-02-23	inibidores de pi3k/mtor quinase
BRPI0910346A2 (pt)	2015-10-06	compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso
HUS1900029I1 (hu)	2020-04-28	Kináz inhibitor foszforszármazékok
CY2017012I2 (el)	2017-11-14	Αναστολεις κινασης τυροσινης bruton
CR10369A (es)	2009-01-09	Pyrimidine derivatives as pi3k inhibitors
BRPI0915231A2 (pt)	2018-06-12	compostos inibidores de quinase e métodos de uso
DK2848610T3 (da)	2017-11-06	Hæmmere af kinaseaktivitet
BRPI0716781A2 (pt)	2014-11-18	Inibidores da quinase
BRPI0912294A2 (pt)	2015-10-20	compostos de triazina como inibidores de pi3 quinase e de mtor
CR10833A (es)	2009-07-03	Quinazolines for pdk1 inhibition
NO20084665L (no)	2009-01-06	Quinazoliner for PDK1-inhibering
NO20084533L (no)	2009-01-09	Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
DK2277509T3 (da)	2015-04-13	DPP IV inhibitorformuleringer
EP2040546A4 (en)	2009-12-23	tyrosine kinase inhibitor
BR112012008483A2 (pt)	2019-09-24	combunações de um inibidor de pi3k e um inibidor de mex
BRPI0717928A2 (pt)	2013-11-05	Imidazopiridazinas como inibidores da cinase de lipídio pi3k
EP2038272A4 (en)	2011-01-05	PYRIDINONYL-PDK1 INHIBITORS
SMP200800022B (it)	2008-04-02	Benzimidazoli sostituiti come inibitori delle chinasi
ES2402426T8 (es)	2013-05-30	Sonda médica
DK2402317T3 (da)	2013-10-07	DGAT-inhibitor
DK1986650T3 (da)	2012-08-13	Manipulationssikre doserignsformer
ATE506358T1 (de)	2011-05-15	2-benzylpyridazinonderivate als met-kinasehemmer
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase